ULTRAVATE

Peak

halobetasol propionate

NDATOPICALLOTION
Approved
Nov 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2

Clinical Trials (2)

NCT04720105Phase 4Completed

Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis

Started Nov 2020
NCT02785172Phase 2Completed

Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis

Started Apr 2016

Loss of Exclusivity

LOE Date
Jun 19, 2033
88 months away
Patent Expiry
Jun 19, 2033

Patent Records (1)

Patent #ExpiryTypeUse Code
8962028
Jun 19, 2033
Product
U-1775